High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na

Antineoplastic Agents / isolation & purification Drug Evaluation, Preclinical / methods Fibroblast Growth Factors / agonists HEK293 Cells High-Throughput Screening Assays / methods Humans Multiprotein Complexes / agonists NAV1.6 Voltage-Gated Sodium Channel / drug effects Protein Binding Protein Interaction Maps / physiology Voltage-Gated Sodium Channel Agonists / isolation & purification Voltage-Gated Sodium Channel Blockers / isolation & purification Voltage-Gated Sodium Channels / drug effects

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 13 06 2019
accepted: 28 10 2019
entrez: 16 11 2019
pubmed: 16 11 2019
medline: 13 11 2020
Statut: epublish

Résumé

Multiple voltage-gated Na

Identifiants

DOI: 10.1038/s41598-019-53110-8 PMID: 31729429 PMC: PMC6858373
pubmed: 31729429
doi: 10.1038/s41598-019-53110-8
pii: 10.1038/s41598-019-53110-8
pmc: PMC6858373
doi:

Substances chimiques

Antineoplastic Agents 0
Multiprotein Complexes 0
NAV1.6 Voltage-Gated Sodium Channel 0
Voltage-Gated Sodium Channel Agonists 0
Voltage-Gated Sodium Channel Blockers 0
Voltage-Gated Sodium Channels 0
fibroblast growth factor 14 0
Fibroblast Growth Factors 62031-54-3

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16890

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH095995
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH111107
Pays : United States
Organisme : NIH HHS
ID : S10 OD023576
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG051131
Pays : United States

Références

Mol Cell Neurosci. 2013 Sep;56:393-403
pubmed: 23891806
Front Cell Neurosci. 2019 Jan 21;12:509
pubmed: 30718999
FEBS Lett. 2002 Mar 27;515(1-3):119-26
pubmed: 11943206
Front Pharmacol. 2017 Aug 15;8:533
pubmed: 28860990
Neurobiol Dis. 2014 Jan;61:55-71
pubmed: 24076101
Science. 2006 Apr 21;312(5772):377-8
pubmed: 16627730
Curr Opin Drug Discov Devel. 2010 Sep;13(5):559-67
pubmed: 20812147
Nat Chem Biol. 2007 Aug;3(8):466-79
pubmed: 17637779
J Biol Chem. 2013 Jul 5;288(27):19370-85
pubmed: 23640885
Front Cell Neurosci. 2017 Apr 19;11:103
pubmed: 28469558
J Biol Chem. 2016 May 20;291(21):11268-84
pubmed: 26994141
Front Cell Neurosci. 2015 Jun 04;9:205
pubmed: 26089778
Curr Med Chem. 2010;17(16):1719-29
pubmed: 20345347
Cerebellum. 2019 Jun;18(3):649-653
pubmed: 30607796
Front Synaptic Neurosci. 2018 Apr 26;10:6
pubmed: 29760657
Brain. 2017 Jun 1;140(6):1579-1594
pubmed: 28444220
Assay Drug Dev Technol. 2012 Apr;10(2):148-60
pubmed: 22364545
Curr Drug Discov Technol. 2004 Jan;1(1):91-6
pubmed: 16472222
Austin J Pharmacol Ther. 2013 Dec 31;1(2):
pubmed: 25485305
Annu Rev Pharmacol Toxicol. 2014;54:165-84
pubmed: 24111540
Epilepsy Behav. 2019 Mar;92:332-340
pubmed: 30769278
J Neurosci. 2007 Oct 31;27(44):12033-44
pubmed: 17978045
Front Psychiatry. 2014 Aug 21;5:109
pubmed: 25191280
Eur J Med Genet. 2019 Mar;62(3):172-176
pubmed: 30017992
EMBO J. 2001 Nov 1;20(21):5950-61
pubmed: 11689435
Bioorg Med Chem Lett. 2019 Feb 1;29(3):413-419
pubmed: 30587448
Cell Rep. 2018 Apr 10;23(2):555-567
pubmed: 29642012
Neuropsychopharmacology. 2009 Jan;34(1):126-41
pubmed: 18800065
Transl Psychiatry. 2016 May 10;6:e806
pubmed: 27163207
EMBO Rep. 2012 Oct;13(10):900-8
pubmed: 22964758
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1250-H1257
pubmed: 30118344
Protein Cell. 2017 Jun;8(6):401-438
pubmed: 28150151
Biochem Biophys Res Commun. 2010 Aug 27;399(3):313-7
pubmed: 20674547
Epilepsy Res. 2014 May;108(4):806-10
pubmed: 24582454
Leuk Lymphoma. 2019 May;60(5):1343-1345
pubmed: 30668266
J Pathol. 2008 Jan;214(2):149-60
pubmed: 18161752
Neurosci Lett. 2018 Feb 22;667:17-26
pubmed: 28522348
Chem Biol. 2014 Oct 23;21(10):1278-1292
pubmed: 25308275
Proteomes. 2019 Jan 23;7(1):
pubmed: 30678040
J Neurosci. 2015 Apr 29;35(17):6752-69
pubmed: 25926453
Biol Cell. 2003 Oct;95(7):437-45
pubmed: 14597261
Mol Pharmacol. 2015 Sep;88(3):579-88
pubmed: 26134495
Mol Cell Neurosci. 2009 Oct;42(2):90-101
pubmed: 19465131
Mol Cell Neurosci. 2008 Aug;38(4):607-15
pubmed: 18599309
FASEB J. 2016 Jun;30(6):2171-86
pubmed: 26917740
J Clin Invest. 2005 Aug;115(8):1986-9
pubmed: 16075038
Elife. 2014 Sep 30;3:e04193
pubmed: 25269146
ACS Chem Neurosci. 2018 May 16;9(5):976-987
pubmed: 29359916
PLoS One. 2015 Feb 06;10(2):e0117246
pubmed: 25659151
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12288-93
pubmed: 15284440
Front Pharmacol. 2010 Aug 20;1:113
pubmed: 21607064
Pharmacol Biochem Behav. 2012 Jan;100(3):566-74
pubmed: 22079349
Recent Pat CNS Drug Discov. 2007 Jan;2(1):57-78
pubmed: 18221218
J Neurochem. 2010 Apr;113(1):27-41
pubmed: 20085610
J Biol Chem. 2009 Jun 26;284(26):17883-96
pubmed: 19406745
Neurogenetics. 2015 Jul;16(3):233-6
pubmed: 25566820
Brain Dev. 2012 Mar;34(3):230-3
pubmed: 21600715
Nat Rev Clin Oncol. 2014 Dec;11(12):704-13
pubmed: 25331179
Mol Cell Biol. 2016 Nov 14;36(23):2967-2982
pubmed: 27644329
Cerebellum Ataxias. 2015 Dec 16;2:19
pubmed: 26677414
Science. 2003 Jun 27;300(5628):2091-4
pubmed: 12829783

Auteurs

Paul A Wadsworth (PA)

MD/PhD Combined Degree Program and Biochemistry and Molecular Biology Graduate Program, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.
Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.
ORCID: 0000-0002-4562-7830

Oluwarotimi Folorunso (O)

Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.

Nghi Nguyen (N)

HTS Screening Core, Center for Translational Cancer Research, Texas A&M Health Science Center: Institute of Biosciences and Technology, Houston, TX, 77030, USA.

Aditya K Singh (AK)

Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.

Daniela D'Amico (D)

Neuroscience Graduate Program, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.

Reid T Powell (RT)

HTS Screening Core, Center for Translational Cancer Research, Texas A&M Health Science Center: Institute of Biosciences and Technology, Houston, TX, 77030, USA.

David Brunell (D)

HTS Screening Core, Center for Translational Cancer Research, Texas A&M Health Science Center: Institute of Biosciences and Technology, Houston, TX, 77030, USA.

John Allen (J)

Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, 77555, USA.

Clifford Stephan (C)

HTS Screening Core, Center for Translational Cancer Research, Texas A&M Health Science Center: Institute of Biosciences and Technology, Houston, TX, 77030, USA.

Fernanda Laezza (F)

Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, Texas, 77555, USA. felaezza@utmb.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › High-throughput screening against...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › High-throughput screening against...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › High-throughput screening against...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › High-throughput screening against...
questionsmedicales.fr › Techniques d'investigation › Tests de criblage à haut débit › High-throughput screening against...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High-throughput screening against...
questionsmedicales.fr › Structures macromoléculaires › Complexes multiprotéiques › High-throughput screening against...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Canaux sodiques voltage-dépendants › Canal sodique voltage-dépendant NAV1.6 › High-throughput screening against...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › High-throughput screening against...
questionsmedicales.fr › Métabolisme › Voies et réseaux métaboliques › Cartes d'interactions protéiques › High-throughput screening against...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Modulateurs du transport transmembranaire › Agonistes de canaux sodiques › Agonistes de canaux sodiques voltage-dépendants › High-throughput screening against...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Bloqueurs de canaux sodiques › Bloqueurs de canaux sodiques voltage-dépendants › High-throughput screening against...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Canaux sodiques voltage-dépendants › High-throughput screening against...